Lamivudine 150 mg - Lamivudine 10 mg/ml

Lamivudine 150 mg - 10 mg/ml - Amilitrap.pdf

Name of the product: AMILITRAP 150

Active ingredient: Lamivudine 150 mg

Dosage form: film-coated tablets

Name of the product: AMILITRAP

Active ingredient: Lamivudine 10 mg/ml (*)

Dosage form: oral solution

Dispensing requirements: Rx only

Argentine Industry

Composition:

AMILITRAP 150:

Each film-coated tablet contains lamivudine 150 mg, avicel PH 200, sodium starch glycolate, lactose DT, cellactose 80, magnesium estearate and OPADRY II HP 85G28725.

AMILITRAP:

Each millilitre of solution contains lamivudine 10 mg, sucrose, methyl hydroxybenzoate, propyl hydroxybenzoate, artificial strawberry flavour, artificial banana flavour, anhydrous citric acid, propylene glycol, disodium edetate, ethanol 96 %, sodium hydroxide or hydrochloric acid and purified water.

Indications:

AMILITRAP in combination with zidovudine is indicated for the treatment of HIV infected adults with progressive immunodeficiency who have not received previous therapy with antiretroviral agents, HIV infected adults with progressive immunodeficiency who have not received previous therapy with zidovudine, and HIV infected infants, from 3 months onwards, with progressive immunodeficiency who have not received previous therapy with zidovudine.

Therapeutic action:

Antiretroviral.

Storage:

AMILITRAP 150:

Keep at temperature below 30º C in the marketed packing.

AMILITRAP 150:

Keep at temperature below 25º C in the marketed packing.

Marketed presentations:

AMILITRAP 150:

Packs containing 60 film-coated tablets.

AMILITRAP (lamivudine 10 mg/5 ml):

Packs containing one 240-ml bottle.

Medicinal speciality authorised by the Ministry of Health.

Certificate Nº 49197

Laboratorio DOSA S.A.

Girardot 1369, (C1427AKC) Buenos Aires, Argentine

Pharmaceutical Director: María C. Terzo, Pharmacist